Hostname: page-component-7b7567c8c-tnzcf Total loading time: 0 Render date: 2026-11-12T19:28:32.205Z Has data issue: false hasContentIssue false
  • English
  • Français

W-18. Workshop: Fate of psychotropic drugs at the blood-brain-barrier and in the brain: Pharmacokinetic, pharmacodynamic and clinical consequences

Published online by Cambridge University Press:  16 April 2020

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Information

Type
Affective disorders
Information
European Psychiatry , Volume 20 , Issue S1: 13th AEP Congress , March 2005, pp. S120
Copyright
Copyright © European Psychiatric Association 2005

P. Baumann. Unite de biochimie et psycho- pharmacologie clinique, Prilly-Lausanne, Switzerland

G. Nikisch. Klinikum Fulda Psychiatrie und Psychotherapie, Fulda, Germany

P. Baumann. Unite de biochimie et psycho- pharmacologie clinique, Prilly-Lausanne, Switzerland

J. Tauscher. Dept. General Psychiatry University Vienna, Vienna, Austria

The in vivo pharmacological effects of psychotropic drugs are expected to depend on their availability in the brain, but this issue has so far been neglected in research. The principal aim of this symposium is to present the relationship between drug concentrations in blood, brain and/or CSF, and their effect on neurotransmitters and neuropeptides, which are measured in blood or CSF of patients treated with antidepressants, and clinical parameters such as therapeutic or adverse effects. Observations obtained with human studies will be compared with those using animal models (pharmacological models, knock-out animals).

Submit a response

Comments

No Comments have been published for this article.